Related Experiment Videos
Limits to the "benefits" from our oncologic interventions: a case report
1Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Gynecologic Oncology
|August 6, 2000
Summary
Aggressive, long-term ovarian cancer treatment can lead to severe side effects, including secondary leukemia. Oncologists must balance treatment benefits against potential harms for long-term survivors.
Area of Science:
- Gynecologic Oncology
- Medical Toxicology
Background:
- Ovarian cancer requires prolonged and aggressive treatment strategies for long-term survival.
- Evaluating the cumulative toxicity of such treatments is crucial for patient outcomes.
Observation:
- A case report details a patient with over 15 years of ovarian cancer history.
- The patient received extensive platinum-based chemotherapy and underwent aggressive surgical interventions.
- She developed severe neurotoxicity and liver metastases.
Findings:
- Despite aggressive treatment, the patient experienced significant treatment-related toxicities, including peripheral neuropathy and hearing loss.
- Resection of asymptomatic liver metastases did not prevent tumor recurrence within a year.
- The patient ultimately died from secondary acute leukemia, a potential consequence of chemotherapy.
Implications:
- This case highlights the critical need to carefully weigh the theoretical benefits of anti-neoplastic therapies against their potential for severe harm in ovarian cancer survivors.
- Oncologists must consider the long-term sequelae and cumulative toxicity when managing patients with persistent or recurrent disease.
- Personalized treatment strategies that minimize long-term adverse effects are essential for improving the quality of life for ovarian cancer survivors.